Lucinda Bateman

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 03:33, May 10, 2018 by Kmdenmark (talk | contribs) (added study and ref)
LucindaBateman.jpeg

Lucinda Bateman (Cindy Bateman), MD, is an ME/CFS doctor and researcher. She founded and is Chief Medical Officer of the Bateman Horne Center of Excellence for ME/CFS and Fibromyalgia in Salt Lake City, Utah. [1]

Dr. Bateman was one of the authors of the 2011 case definition, International Consensus Criteria,[2] and was one of the experts on the "Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" that was convened for the 2015 Institute of Medicine report.[3]

Suzanne Vernon, PhD, the Research Liaison at Bateman Horne Center of Excellence works closely with Dr. Bateman on ME/CFS and fibromyalgia research.[4]

CFSAC Committee[edit | edit source]

Dr. Bateman was a voting member of the Health and Human Services's Chronic Fatigue Syndrome Advisory Committee for the terms 12/01/05 to 12/01/08[5] & 01/03/06 to 01/03/10[6] and is currently serving the term 12/13/2017 to 12/12/2021.[7]

Open Letter to The Lancet[edit | edit source]

Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Bateman, along with 41 colleagues in the ME/CFS field, signed the second letter.

Notable studies[edit | edit source]

Clinic location[edit | edit source]

The Bateman Horne Center 24 S. 1100 E. Suite 205 Salt Lake City, Utah 84102 1-801-359-7400

Talks and interviews[edit | edit source]

Webinars[edit | edit source]

Science to patients / Wetenschap voor patienten

Solve ME/CFS Initiative

IAMECFS Conference[edit | edit source]

Blog posts[edit | edit source]

Awards[edit | edit source]

  • 2016, Rudy Perpich Senior Lectureship Award, presented to a distinguished CFS/FMS scientist, physician or healthcare worker awarded by IACFS/ME[24]

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ https://batemanhornecenter.org/
  2. ↑ Carruthers, BM; van de Sande, MI; De Meirleir, KL; Klimas, NG; Broderick, G; Mitchell, T; Staines, D; Powles, A C P; Speight, N; Vallings, R; Bateman, L; Baumgarten-Austrheim, B; Bell, DS; Carlo-Stella, N; Chia, J; Darragh, A; Jo, D; Lewis, D; Light, A; Marshall-Gradisnik, S; Mena, I; Mikovits, JA; Miwa, K; Murovska, M; Pall, ML; Stevens, S (2011), "Myalgic encephalomyelitis: International Consensus Criteria.", Journal of Internal Medicine, 270 (4): 327-38, doi:10.1111/j.1365-2796.2011.02428.x, PMID 21777306
  3. ↑ http://www.ncbi.nlm.nih.gov/books/NBK284904/
  4. ↑ https://batemanhornecenter.org/suzanne-d-vernon-phd/
  5. ↑ HHS.gov (2006), Nov 20 & 21, 2006 CFSAC Meeting (PDF) (Minutes)
  6. ↑ HHS.gov (2009), May 27 & 28, 2009 CFSAC Meeting (PDF) (Roster)
  7. ↑ https://www.hhs.gov/ash/advisory-committees/cfsac/about-cfsac/roster/index.html
  8. ↑ Montoya, Jose G; Anderson, Jill N; Adolphs, Danya L; Bateman, Lucinda; Klimas, Nancy; Levine, Susan M; Garvert, Donn W; Kaiser, Jon D (2018), "KPAX002 as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A prospective, randomized trial" (PDF), International Journal of Clinical and Experimental Medicine, 11 (3): 2890-2900
  9. ↑ Nagy-Szakal, Dorottya; Williams, Brent L.; Mishra, Nischay; Che, Xiaoyu; Lee, Bohyun; Bateman, Lucinda; Klimas, Nancy G.; Komaroff, Anthony L.; Levine, Susan; Montoya, Jose G.; Peterson, Daniel L.; Ramanan, Devi; Jain, Komal; Eddy, Meredith L.; Hornig, Mady; Lipkin, W. Ian (2017), "Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome", Microbiome, 5 (44), doi:10.1186/s40168-017-0261-y
  10. ↑ Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029
  11. ↑ Baldwin, Nicole L.; Murray, Kristy O.; Garcia, Melissa N.; Bateman, Lucinda (2016), "Treatment of postural orthostatic tachycardia syndrome and management of myalgic encephalomyelitis/chronic fatigue syndrome following suspected West Nile virus infection", Fatigue: Biomedicine, Health & Behavior, 4 (4): 226-236, doi:10.1080/21641846.2016.1247971
  12. ↑ Klimas, N.G.; Ironson, G.; Carter, A.; Balbin, E.; Bateman, L.; Felsenstein, D.; Levine, S.; Peterson, D.; Chiu, K.; Allen, A.; Cunningham, K.; Gottschalk, C.G.; Fletcher, M; Hornig, M.; Canning, C.; Komaroff, A.L. (2015), "Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome", Fatigue: Biomedicine, Health & Behavior, 3 (2): 75-96, doi:10.1080/21641846.2015.1023652
  13. ↑ Bateman, L.; Darakjy, S.; Klimas, N.; Peterson, D.; Levine, S.M.; Allen, A.; Carlson, S.A.; Balbin, E.G.; Gottschalk, G.; March, D. (2015), "Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study", Fatigue: Biomedicine, Health & Behavior, 3 (1): 1-15, doi:10.1080/21641846.2014.978109
  14. ↑ Hornig, M; Montoya, JG; Klimas, NG; Levine, SM; Felsenstein, D; Bateman, L; Peterson, DL; Gottschalk, CG; Schultz, AF; Che, X; Eddy, ML; Komaroff, AL; Lipkin, WI (2015), "Distinct plasma immune signatures in ME/CFS are present early in the course of illness", Science Advances, 1 (1), doi:10.1126/sciadv.1400121
  15. ↑ Light, K.C., Agarwal, N., Iacob, E., White, A.T., Kinney, A.Y., Vanhaitsma, T.A., Aizad, H., Hughen, R.W., Bateman, L., and Light, A.R. (2013) Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. Psychoneuroendocrinology, Sep 6. doi:pii: S0306-4530(13)00297-7. 10.1016/j.psyneuen.2013.08.008
  16. ↑ Irlbeck, D. M., Vernon, S. D., McCleary, K. K., Bateman, L., Klimas, N. G., Lapp, C. W., Peterson, D.L., Brown, J. R., Remlinger, K. S., Wilfret, D. A., and Gerondelis, P. (2014). No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank. BMC Research Notes, 7, 461. http://doi.org/10.1186/1756-0500-7-461
  17. ↑ Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012), "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.", PLoS One, 7 (3): e31334, doi:10.1371/journal.pone.0031334, PMID 22431963
  18. ↑ Alter, Harvey J.; Mikovits, Judy A.; Switzer, William M.; Ruscetti, Francis W.; Lo, Shyh-Ching; Klimas, Nancy; Komaroff, Anthony L.; Montoya, Jose G.; Bateman, Lucinda; Levine, Susan; Peterson, Daniel; Levin, Bruce; Hanson, Maureen R.; Genfi, Afia; Bhat, Meera; Zheng, HaoQiang; Wang, Richard; Li, Bingjie; Hung, Guo-Chiuan; Lee, Li Ling; Sameroff, Stephen; Heneine, Walid; Coffin, John; Hornig, Mady; Lipkin, W. Ian (2012), "A Multicenter Blinded Analysis Indicates No Association between Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and either Xenotropic Murine Leukemia Virus-Related Virus or Polytropic Murine Leukemia Virus", mBio, 3 (5): e00266–12, doi:10.1128/mBio.00266-12
  19. ↑ Light, Alan R; Bateman, Lucinda; Jo, Daehyun; Hughen, RW; Vanhaitsma, TA; White, AT; Light, Kathleen (2012), "Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome", Journal of Internal Medicine, 271 (1): 64-81, doi:10.1111/j.1365-2796.2011.02405.x
  20. ↑ Shin CH, Bateman L, Schlaberg R, Bunker AM, Leonard CJ, Hughen RW, Light AR, Light KC, Singh IR. (2011) Absence of XMRV retrovirus and other murine leukemia virus-related viruses in patients with chronic fatigue syndrome. Journal of Virology. 2011 Jul;85(14):7195-202. doi: 10.1128/JVI.00693-11.
  21. ↑ Albright, Frederick; Light, Kathleen; Light, Alan; Bateman, Lucinda; Cannon-Albright, Lisa A (2011), "Evidence for a heritable predisposition to Chronic Fatigue Syndrome", BMC Neurology, 11 (62), doi:10.1186/1471-2377-11-62
  22. ↑ White, A.T., Light, A.R., Hughen, R.W., Bateman, L., Martins, T.B., Hill, H.R., and Light, K.C. (2010) Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. Psychophysiology, 47(4):615-24. doi: 10.1111./j.1469-8986.2010.00978.x
  23. ↑ Fennell, P. A., & Bateman, L. (2005). "A team approach to treating CFS: Matching best medical practices to phases of illness." CFS Research Review, Summer.
  24. ↑ https://twitter.com/BatemanHorne/status/792750279758323712

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

Chronic Fatigue Syndrome Advisory Committee (CFSAC) - (sometimes pronounced SIF-SACK) A US government advisory council that met twice per year, covering current topics related to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Meetings usually lasted for two days and the results were presented to the Secretary of Health and Human Services (HHS). After 15 years, on September 5, 2018, CFSAC's charter was not renewed by the Department of HHS, effectively dissolving the committee without notice or warning.

blinded trial A clinical trial is blinded if either the participants or the researchers don't know which treatment group they are allocated to until after the results are interpreted. (Learn more: www.nottingham.ac.uk)

double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)

agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.

flare-up A symptoms flare in ME/CFS is a temporary increase in symptoms, alternatively known as experiencing post-exertional malaise. May be referred to as a "crash" or "collapse".

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

microbiome The full collection of microscopic organisms (especially bacteria and fungi) which are present in a particular environment, particularly inside the human body.

tachycardia An unusually rapid heart beat. Can be caused by exercise or illness. A symptom of postural orthostatic tachycardia syndrome (POTS). (Learn more: www.heart.org)

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

Retrieved from "https://me-pedia.org/w/index.php?title=Lucinda_Bateman&oldid=30562"